small cell carcinoma

(redirected from Small cell lung carcinoma)
Also found in: Thesaurus, Medical, Acronyms.
Related to Small cell lung carcinoma: Non-small cell lung cancer, NSCLC

small cell carcinoma

ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.small cell carcinoma - highly malignant carcinoma composed of small round or egg-shaped cells with little cytoplasmsmall cell carcinoma - highly malignant carcinoma composed of small round or egg-shaped cells with little cytoplasm; lung cancers are frequently oat cell carcinomas
carcinoma - any malignant tumor derived from epithelial tissue; one of the four major types of cancer
References in periodicals archive ?
For example, it can help differentiate between lung adenocarcinoma and squamous cell carcinoma (SqCC), lung adenocarcinoma and malignant mesothelioma (MM), primary and metastatic carcinomas, and small cell lung carcinoma (SCLC) and carcinoid tumor.
They discuss the epidemiology of central nervous system metastases, the involvement of the CXCL12/CXCR4/CXCR7 axis, non-uniform distribution of metastatic intracranial tumors in cancer patients, targeting angiogenesis, enhancing radiosensitization, crossing the blood-brain barrier, second malignancies in children following treatment for neuroblastoma, the role of chemotherapy, whole brain radiotherapy for multiple metastases to the brain from primary cancers, and synovial sarcoma metastasized to the brain; brain metastases from non-small cell lung carcinoma; and brain metastases from small cell lung carcinoma.
It demonstrates high accuracy in distinguishing between small cell lung carcinoma and non-small cell lung carcinoma, a clinically important differentiation.
Small cell lung carcinoma which constitutes 20% is in the extensive stage when diagnosed in 70% of patients.
The high mortality rate is attributed to its early metastasis, particularly for non small cell lung carcinoma (NSCLC).
Small cell lung carcinoma (SCLC) is an aggressive neoplasm that can be associated with cerebral metastases in 10% of affected patients, at the time of their initial presentation; this may be present in 65% of patients at the time of autopsy.
Coexpression of transcripts Encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma.
During the lengthy application process, many proofs of the application were required by the United States Patent and Trademark Office for a patent of such relevance and applicability to all cancers to be approved, and included proofs in multiple forms of cancer tumors including small cell lung carcinoma and melanoma cancer.
The milestone, which triggers a $500,000 payment, relates to reaching the halfway mark in study enrollment in its multinational Phase III clinical trial of BEC2 in patients with limited disease small cell lung carcinoma.
Utility of the quantitative Ki-67 proliferation index and CD56 together in the cytologic diagnosis of small cell lung carcinoma and other lung neuroendocrine tumors.